vs
Side-by-side financial comparison of Varex Imaging Corp (VREX) and VIRTUS INVESTMENT PARTNERS, INC. (VRTS). Click either name above to swap in a different company.
Varex Imaging Corp is the larger business by last-quarter revenue ($209.6M vs $199.5M, roughly 1.1× VIRTUS INVESTMENT PARTNERS, INC.). VIRTUS INVESTMENT PARTNERS, INC. runs the higher net margin — 3.6% vs 1.1%, a 2.5% gap on every dollar of revenue. On growth, Varex Imaging Corp posted the faster year-over-year revenue change (4.9% vs -4.1%). Over the past eight quarters, Varex Imaging Corp's revenue compounded faster (0.8% CAGR vs -5.7%).
Varex Imaging Corp is a global supplier of advanced imaging components and solutions, including X-ray tubes, digital flat panel detectors, and image processing software. Its products serve medical imaging, radiation oncology, and industrial non-destructive testing segments, with customers across key global markets.
VIRTUS INVESTMENT PARTNERS, INC.VRTSEarnings & Financial Report
Virtus Investment Partners, Inc. is an American company which operates as a multi-manager asset management business, comprising a number of individual affiliated managers, each having its own investment process and brand, and the services of unaffiliated sub advisers.
VREX vs VRTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $209.6M | $199.5M |
| Net Profit | $2.3M | $7.1M |
| Gross Margin | 33.3% | — |
| Operating Margin | 7.3% | 7.7% |
| Net Margin | 1.1% | 3.6% |
| Revenue YoY | 4.9% | -4.1% |
| Net Profit YoY | 866.7% | -78.1% |
| EPS (diluted) | $0.05 | $1.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $209.6M | $199.5M | ||
| Q4 25 | $228.9M | $208.0M | ||
| Q3 25 | $203.0M | $216.4M | ||
| Q2 25 | $212.9M | $210.5M | ||
| Q1 25 | $199.8M | $217.9M | ||
| Q4 24 | — | $233.5M | ||
| Q3 24 | $205.7M | $227.0M | ||
| Q2 24 | $209.1M | $224.4M |
| Q1 26 | $2.3M | $7.1M | ||
| Q4 25 | $12.2M | $33.9M | ||
| Q3 25 | $-89.1M | $31.3M | ||
| Q2 25 | $6.9M | $42.7M | ||
| Q1 25 | $-300.0K | $28.1M | ||
| Q4 24 | — | $39.5M | ||
| Q3 24 | $-51.1M | $49.1M | ||
| Q2 24 | $1.4M | $26.0M |
| Q1 26 | 33.3% | — | ||
| Q4 25 | 34.0% | — | ||
| Q3 25 | 33.3% | — | ||
| Q2 25 | 36.0% | — | ||
| Q1 25 | 34.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 32.6% | — | ||
| Q2 24 | 32.0% | — |
| Q1 26 | 7.3% | 7.7% | ||
| Q4 25 | 8.6% | 19.1% | ||
| Q3 25 | -39.8% | 21.7% | ||
| Q2 25 | 10.4% | 21.5% | ||
| Q1 25 | 5.6% | 16.8% | ||
| Q4 24 | — | 21.7% | ||
| Q3 24 | 5.3% | 24.3% | ||
| Q2 24 | 4.4% | 19.7% |
| Q1 26 | 1.1% | 3.6% | ||
| Q4 25 | 5.3% | 16.3% | ||
| Q3 25 | -43.9% | 14.5% | ||
| Q2 25 | 3.2% | 20.3% | ||
| Q1 25 | -0.2% | 12.9% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | -24.8% | 21.6% | ||
| Q2 24 | 0.7% | 11.6% |
| Q1 26 | $0.05 | $1.05 | ||
| Q4 25 | $0.29 | $5.15 | ||
| Q3 25 | $-2.15 | $4.65 | ||
| Q2 25 | $0.17 | $6.12 | ||
| Q1 25 | $-0.01 | $4.05 | ||
| Q4 24 | — | $4.65 | ||
| Q3 24 | $-1.25 | $5.71 | ||
| Q2 24 | $0.03 | $2.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $125.6M | $136.6M |
| Total DebtLower is stronger | $367.6M | — |
| Stockholders' EquityBook value | $476.9M | $93.6B |
| Total Assets | $1.1B | — |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $125.6M | $136.6M | ||
| Q4 25 | $155.1M | — | ||
| Q3 25 | $152.6M | — | ||
| Q2 25 | $223.0M | — | ||
| Q1 25 | $212.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $200.5M | — | ||
| Q2 24 | $190.0M | — |
| Q1 26 | $367.6M | — | ||
| Q4 25 | $367.5M | $390.0M | ||
| Q3 25 | $367.5M | $390.6M | ||
| Q2 25 | $567.2M | $231.3M | ||
| Q1 25 | $567.0M | $231.7M | ||
| Q4 24 | — | $232.1M | ||
| Q3 24 | $443.4M | $237.5M | ||
| Q2 24 | $443.1M | $247.6M |
| Q1 26 | $476.9M | $93.6B | ||
| Q4 25 | $472.6M | $934.0M | ||
| Q3 25 | $455.3M | $918.7M | ||
| Q2 25 | $549.7M | $896.4M | ||
| Q1 25 | $540.2M | $893.7M | ||
| Q4 24 | — | $897.5M | ||
| Q3 24 | $529.1M | $889.0M | ||
| Q2 24 | $581.2M | $868.7M |
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $4.3B | ||
| Q3 25 | $1.1B | $3.9B | ||
| Q2 25 | $1.4B | $3.7B | ||
| Q1 25 | $1.3B | $3.7B | ||
| Q4 24 | — | $4.0B | ||
| Q3 24 | $1.2B | $3.6B | ||
| Q2 24 | $1.3B | $3.6B |
| Q1 26 | 0.77× | — | ||
| Q4 25 | 0.78× | 0.42× | ||
| Q3 25 | 0.81× | 0.43× | ||
| Q2 25 | 1.03× | 0.26× | ||
| Q1 25 | 1.05× | 0.26× | ||
| Q4 24 | — | 0.26× | ||
| Q3 24 | 0.84× | 0.27× | ||
| Q2 24 | 0.76× | 0.29× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.1M | — |
| Free Cash FlowOCF − Capex | $-26.8M | — |
| FCF MarginFCF / Revenue | -12.8% | — |
| Capex IntensityCapex / Revenue | 5.1% | — |
| Cash ConversionOCF / Net Profit | -7.00× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $-16.1M | — | ||
| Q4 25 | $7.9M | $-67.2M | ||
| Q3 25 | $7.7M | $108.3M | ||
| Q2 25 | $16.6M | $75.8M | ||
| Q1 25 | $9.5M | $-3.8M | ||
| Q4 24 | — | $1.8M | ||
| Q3 24 | $25.9M | $69.1M | ||
| Q2 24 | $8.0M | $70.0M |
| Q1 26 | $-26.8M | — | ||
| Q4 25 | $2.3M | $-74.1M | ||
| Q3 25 | $1.4M | $106.9M | ||
| Q2 25 | $9.8M | $74.2M | ||
| Q1 25 | $5.3M | $-6.8M | ||
| Q4 24 | — | $-3.8M | ||
| Q3 24 | $19.9M | $68.7M | ||
| Q2 24 | $3.3M | $68.6M |
| Q1 26 | -12.8% | — | ||
| Q4 25 | 1.0% | -35.6% | ||
| Q3 25 | 0.7% | 49.4% | ||
| Q2 25 | 4.6% | 35.2% | ||
| Q1 25 | 2.7% | -3.1% | ||
| Q4 24 | — | -1.6% | ||
| Q3 24 | 9.7% | 30.3% | ||
| Q2 24 | 1.6% | 30.6% |
| Q1 26 | 5.1% | — | ||
| Q4 25 | 2.4% | 3.3% | ||
| Q3 25 | 3.1% | 0.7% | ||
| Q2 25 | 3.2% | 0.7% | ||
| Q1 25 | 2.1% | 1.4% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | 2.9% | 0.2% | ||
| Q2 24 | 2.2% | 0.6% |
| Q1 26 | -7.00× | — | ||
| Q4 25 | 0.65× | -1.99× | ||
| Q3 25 | — | 3.45× | ||
| Q2 25 | 2.41× | 1.77× | ||
| Q1 25 | — | -0.13× | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | 5.71× | 2.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VREX
| Medical Segment | $144.8M | 69% |
| Industrial Segment | $64.8M | 31% |
VRTS
| Investment management fees | $169.1M | 85% |
| Administration and shareholder service fees | $17.3M | 9% |
| Distribution and service fees | $11.6M | 6% |
